Key Takeaways
- On April 14, two Conagra board members purchased a total of 42,500 shares, investing approximately $609,000 as the stock traded near its lowest point in twelve months.
- Shares of CAG have declined 17% during 2026, pressured by weakening sales volumes, compressed margins, and reduced full-year guidance.
- The company’s fiscal third quarter results disappointed with earnings per share of $0.39 versus the expected $0.40, while revenues declined 1.9% compared to the prior year.
- Morgan Stanley reduced its price objective to $15 from $17 this Thursday, maintaining an “equal weight” stance on the shares.
- Wall Street consensus stands at “Reduce” with a mean price objective of $15.80 — consisting of 1 Buy rating, 13 Hold ratings, and 4 Sell ratings.
Two members of Conagra’s board of directors recently demonstrated their conviction by making substantial stock purchases. Richard H. Lenny, a director, acquired 25,000 shares of CAG stock on April 14 at a price of $14.34 per share, representing a total investment of $358,500. Fellow director John J. Mulligan purchased 17,500 shares at $14.31 on the identical date, committing $250,425 to the transaction.
The aggregate investment of approximately $609,000 occurred while shares traded close to their 12-month nadir of $14.04. Mulligan’s acquisition boosted his stake in the company by an impressive 542%. Following his purchase, Lenny’s total holdings reached 229,340 shares with a current market value of roughly $3.3 million.
The purchases arrived at a critical juncture. CAG’s recent slide commenced on April 9 following BNP Paribas’ decision to downgrade the stock from Outperform to Neutral while reducing its price objective dramatically from $19 to $16. Shares closed beneath $16 that very session.
The situation intensified shortly thereafter. On April 13, Conagra announced the appointment of John Brase as incoming CEO and president. Jefferies noted that Brase would inherit “high leverage, ongoing inflationary pressures, and margin compression.”
Disappointing Quarterly Results Compound Concerns
Earlier in April, Conagra unveiled fiscal third quarter financial results that fell short of analyst projections. The food manufacturer reported earnings per share of $0.39, trailing the consensus estimate of $0.40 by one cent. Revenue registered at $2.79 billion, marginally exceeding the anticipated $2.76 billion.
However, the modest revenue outperformance provided little relief. Sales decreased 1.9% on a year-over-year basis, while the company generated $0.51 in EPS during the comparable quarter last year — representing a substantial decline. Conagra additionally lowered its expectations for the complete fiscal year, attributing the revision to challenging macroeconomic conditions and continued inflationary headwinds.
Shares have tumbled 17% since the beginning of 2026. By comparison, the S&P 500 has advanced 4.2% during the identical timeframe.
Wall Street Maintains Conservative Outlook
Equity analysts have shown little eagerness to turn bullish on the stock. This Thursday, Morgan Stanley trimmed its price target on CAG to $15 from a previous $17, while maintaining its “equal weight” rating. That revised target suggests merely 3.6% potential upside based on Wednesday’s closing price.
Morgan Stanley’s adjustment follows a broader pattern. JPMorgan lowered its target from $19 to $17 during March. TD Cowen and Deutsche Bank each moved their objectives down to $14. Stifel implemented a reduction to $15 this week.
According to MarketBeat’s current analyst compilation, CAG holds 1 Buy rating, 13 Hold ratings, and 4 Sell ratings, yielding an average price target of $15.80 and an overall “Reduce” consensus.
CAG commenced trading Thursday at $14.49. The stock’s 50-day moving average stands at $16.75 while the 200-day moving average rests at $17.38, both substantially above current trading levels.
One notable metric: CAG presently offers a dividend yield approaching 9%, representing the highest dividend yield among all S&P 500 constituents. The average yield for dividend-paying companies within the index is 2.3%.
Institutional investors collectively control 83.75% of outstanding shares. Multiple smaller funds have expanded their positions during recent quarters, though the additions have been relatively modest in scale.
